19 insiders have filed at JNJ since 2023Q3: names, roles, reported stakes, and each person's buying and selling record from SEC Form 3/4/5 filings.
| name | role | reported stake | % of company | buys (3y) | sells (3y) |
|---|---|---|---|---|---|
| Duato Joaquin | CEO And Chairman Of The Board | 356.3k | 0.015% | 3 sells $44.7M | |
| Taubert Jennifer L | EVP, Wwc. Innovative Medicine | 194.5k | <0.01% | 2 sells $19.3M | |
| Wengel Kathryn E | EVP, Chief To And Risk Officer | 114.7k | <0.01% | ||
| Fasolo Peter | Exec VP, Chief Hr Officer | 112.1k | <0.01% | 1 sells $3.4M | |
| Wolk Joseph J | Exec VP, CFO | 85.0k | <0.01% | 6 sells $26.7M | |
| Mcevoy Ashley | EVP, Ww Chair, Medtech | 55.1k | <0.01% | ||
| Hait William | See Remarks | 38.6k | <0.01% | 1 sells $2.5M | |
| Schmid Timothy | EVP, Ww Chair, Medtech | 26.2k | <0.01% | 4 sells $5.9M | |
| Swanson James D. | EVP, CIO | 25.7k | <0.01% | 3 sells $15.1M | |
| Decker Robert J | VP Corporate Controller | 24.5k | <0.01% | 3 sells $3.1M | |
| Forminard Elizabeth | EVP, Chief Legal Officer | 23.6k | <0.01% | ||
| Broadhurst Vanessa | EVP, Global Corp Affairs | 23.0k | <0.01% | 2 sells $3.0M | |
| Mulholland Kristen | EVP, Chief Hr Officer | 19.8k | <0.01% | ||
| Reed John C | EVP, Innovative Medicine, R&d | 10.7k | <0.01% | 5 sells $20.4M | |
| Morikis John G | Director | 1.8k | <0.01% | 1 buys $258k | |
| Weinberger Mark A | Director | 1.0k | <0.01% | 1 buys $147k | |
| Woods Eugene A. | Director | 250 | <0.01% | 1 buys $15k | |
| Johnson Paula A | Director | 89 | <0.01% | ||
| Pinto Daniel E | Director |
Full register at boothcheck.com/insiders/JNJ. Stakes are the newest reported Form 3/4/5 balances (they update only when insiders file). Sales counted include pre-scheduled plan sales, labeled. A filed record, not a forecast. Nothing here is investment advice.